Key Findings: 
Type of Study: 
Study Result:  Inconclusive
Research Location(s): 
Year of Pub: 
Cannabinoids Studied: 
Chemotype: 
Terpenes Studied: 
Receptors Studied: 
Ligands Studied: 
DOSING DETAILS   
Study Dosing Objective:  Effective Dose,
Established Protocol:  Effective dose
Route of Administration: 
Cannabinoid Ratio:  (THC : CBD)   19 : 9    
Dosage Form:  19% THC or 19% THC with 9% CBD
Dosing Regimen:  200 mg was effective in reducing migraine pain by 55% 200 mg of THC with CBD was superior to amitriptyline
Adverse Events:  Somnolence with an edible form of medical cannabis. 23.1% in one study reported adverse effects, and 1.3% of those cases discontinued medical cannabis, but no severe adverse effects were reported.
Citation: